KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Acquisitions & Divestments (2017 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Change in Acquisitions & Divestments for 11 consecutive years, with $123.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 25.19% to $123.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $574.5 million, a 17.98% decrease, with the full-year FY2025 number at $574.5 million, down 17.98% from a year prior.
  • Change in Acquisitions & Divestments was $123.9 million for Q4 2025 at Xenon Pharmaceuticals, up from $113.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $235.7 million in Q2 2024 to a low of $20.3 million in Q1 2022.
  • A 5-year average of $118.4 million and a median of $128.9 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 55.87% in 2022, then surged 674.7% in 2023.
  • Xenon Pharmaceuticals' Change in Acquisitions & Divestments stood at $42.3 million in 2021, then skyrocketed by 147.8% to $104.8 million in 2022, then soared by 30.66% to $136.9 million in 2023, then rose by 21.01% to $165.6 million in 2024, then dropped by 25.19% to $123.9 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Change in Acquisitions & Divestments are $123.9 million (Q4 2025), $113.5 million (Q3 2025), and $171.2 million (Q2 2025).